Abstract
Background
To explore how urologists manage prostate cancer (PCa) screening and treatment in patients undergoing endoscopic enucleation of the prostate (EEP).
Methods
A team of experts in EEP collaboratively formulated the survey questions through an interactive process. The survey opened in January 2024 and closed in February 2024.
Results
102 urologists responded, revealing that most use PSA and digital rectal examination for screening, with high PSA and abnormal DRE prompting prostate MRI. 75% perform pre-EEP biopsies. For incidental low-grade PCa, active surveillance is preferred. For intermediate-grade PCa, most use PSA and MRI for workup, often choosing active surveillance if post-EEP biopsies are negative. There’s no consensus on abnormal post-operative PSA thresholds.
Conclusions
While urologists are aware of PCa management in EEP candidates, future work should focus on developing optimal post-EEP screening protocols.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Capitanio U, Autorino R, Bandini M, Briganti A, Cheng L, Cooperberg MR, et al. Incidental prostate cancer (cT1a-cT1b) is a relevant clinical and research entity and should be fully discussed in the international prostate cancer guidelines. Eur Urol Oncol. 2021;S2588-9311:00049–3.
Eysenbach G. Improving the quality of web surveys: the checklist for reporting results of internet e-surveys (CHERRIES). J Med Internet Res. 2004;6:e34.
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;S0302-2838:02254–1.
Gravas S, Gacci M, Gratzke C, Herrmann TRW, Karavitakis M, Kyriazis I, et al. Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms. Eur Urol. 2023;84:207–22.
Grey ADR, Scott R, Shah B, Acher P, Liyanage S, Pavlou M, et al. Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study. Lancet Oncol. 2022;23:428–38.
Lee MS, Assmus MA, Guo J, Siddiqui MR, Ross AE, Krambeck AE. Relationships between holmium laser enucleation of the prostate and prostate cancer. Nat Rev Urol. 2023;20:226–40.
Abedali ZA, Calaway AC, Large T, Lingeman JE, Mellon MJ, Boris RS. The role of prostate specific antigen monitoring after holmium laser enucleation of the prostate. J Urol. 2020;203:304–10.
Mottet N, Rouviere O, van der Kwast TH. Incidental prostate cancer: a real need for expansion in guidelines? Eur Urol Oncol. 2022;5:259–60.
Baboudjian M, Breda A, Rajwa P, Gallioli A, Gondran-Tellier B, Sanguedolce F, et al. Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression. Eur Urol Oncol. 2022;5:617–27.
Hutchison D, Peabody H, Kuperus JM, Humphrey JE, Ryan M, Moriarity A, et al. Management of prostate cancer after holmium laser enucleation of the prostate. Urol Oncol. 2021;39:297.e1–297.e8.
Author information
Authors and Affiliations
Contributions
AU: Project development, data collection, data analysis, and manuscript drafting. JNC: project development, critical revision of the manuscript; BP: project development, critical revision of the manuscript; TRWH: project development, critical revision of the manuscript; VM: project development, critical revision of the manuscript; MR: critical revision of the manuscript; CDN: project development, critical revision of the manuscript; HH: project development, critical revision of the manuscript; GP: project development, critical revision of the manuscript; MB project development, data analysis, drafting of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors have nothing to disclose. Alessandro Uleri had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Uleri, A., Cornu, J.N., Pradere, B. et al. Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey. Prostate Cancer Prostatic Dis 28, 837–839 (2025). https://doi.org/10.1038/s41391-024-00909-w
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41391-024-00909-w
This article is cited by
-
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study
Prostate Cancer and Prostatic Diseases (2025)
